Factors associated with variation in estimates of the cost of resistant infections

Bevin Cohen, Elaine L. Larson, Patricia W. Stone, Matthew Neidell, Sharon Glied

Research output: Contribution to journalArticle

Abstract

Background: Existing estimates of the costs of antimicrobial resistance exhibit broad variability, and the contributing factors are not well understood. This study examines factors that contribute to variation in these estimates. Methods: Studies of the costs of resistant infections (1995-2009) were identified, abstracted, and stated in comparable terms (eg, converted to 2007 U.S. dollars). Linear regressions were conducted to assess how costs incurred by patients with resistant infections versus those incurred by uninfected or susceptible-organism-infected controls varied according to (1) costs incurred by control subjects; (2) study population characteristics; (3) methodological factors (eg, matching); and (4) length of stay. Results: Estimates of difference in costs incurred by patients with resistant infections versus patients without resistant infections varied between $-27,609 (control costs exceeded case costs) and $126,856. Differences were greater when the costs incurred by control subjects were higher (ie, when the underlying cost of care was high). Study-adjusted cost differences were greater for bloodstream infections (vs. any other infection site), for studies that reported median (vs. mean) costs, for studies that reported total (vs. postinfection or infection-associated) costs, for studies that used uninfected (vs. susceptible-organism-infected) controls, and for studies that did not match or adjust for length of stay before infection. Conclusion: The cost of antimicrobial resistance seems to vary with the underlying cost of care. Increased costs of resistance are partially explained by longer length of stay for patients with resistant infections. Further research is needed to assess whether interventions should be differentially targeted at the highest cost cases.

Original languageEnglish (US)
Pages (from-to)767-775
Number of pages9
JournalMedical Care
Volume48
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Costs and Cost Analysis
Infection
Cost Control
Length of Stay
Population Characteristics
Linear Models
Research

Keywords

  • antibiotic resistance
  • hospital costs
  • length of stay

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Factors associated with variation in estimates of the cost of resistant infections. / Cohen, Bevin; Larson, Elaine L.; Stone, Patricia W.; Neidell, Matthew; Glied, Sharon.

In: Medical Care, Vol. 48, No. 9, 09.2010, p. 767-775.

Research output: Contribution to journalArticle

Cohen, Bevin ; Larson, Elaine L. ; Stone, Patricia W. ; Neidell, Matthew ; Glied, Sharon. / Factors associated with variation in estimates of the cost of resistant infections. In: Medical Care. 2010 ; Vol. 48, No. 9. pp. 767-775.
@article{3d5c09fa0e2b47bc9f31265c38c025a1,
title = "Factors associated with variation in estimates of the cost of resistant infections",
abstract = "Background: Existing estimates of the costs of antimicrobial resistance exhibit broad variability, and the contributing factors are not well understood. This study examines factors that contribute to variation in these estimates. Methods: Studies of the costs of resistant infections (1995-2009) were identified, abstracted, and stated in comparable terms (eg, converted to 2007 U.S. dollars). Linear regressions were conducted to assess how costs incurred by patients with resistant infections versus those incurred by uninfected or susceptible-organism-infected controls varied according to (1) costs incurred by control subjects; (2) study population characteristics; (3) methodological factors (eg, matching); and (4) length of stay. Results: Estimates of difference in costs incurred by patients with resistant infections versus patients without resistant infections varied between $-27,609 (control costs exceeded case costs) and $126,856. Differences were greater when the costs incurred by control subjects were higher (ie, when the underlying cost of care was high). Study-adjusted cost differences were greater for bloodstream infections (vs. any other infection site), for studies that reported median (vs. mean) costs, for studies that reported total (vs. postinfection or infection-associated) costs, for studies that used uninfected (vs. susceptible-organism-infected) controls, and for studies that did not match or adjust for length of stay before infection. Conclusion: The cost of antimicrobial resistance seems to vary with the underlying cost of care. Increased costs of resistance are partially explained by longer length of stay for patients with resistant infections. Further research is needed to assess whether interventions should be differentially targeted at the highest cost cases.",
keywords = "antibiotic resistance, hospital costs, length of stay",
author = "Bevin Cohen and Larson, {Elaine L.} and Stone, {Patricia W.} and Matthew Neidell and Sharon Glied",
year = "2010",
month = "9",
doi = "10.1097/MLR.0b013e3181e358b9",
language = "English (US)",
volume = "48",
pages = "767--775",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Factors associated with variation in estimates of the cost of resistant infections

AU - Cohen, Bevin

AU - Larson, Elaine L.

AU - Stone, Patricia W.

AU - Neidell, Matthew

AU - Glied, Sharon

PY - 2010/9

Y1 - 2010/9

N2 - Background: Existing estimates of the costs of antimicrobial resistance exhibit broad variability, and the contributing factors are not well understood. This study examines factors that contribute to variation in these estimates. Methods: Studies of the costs of resistant infections (1995-2009) were identified, abstracted, and stated in comparable terms (eg, converted to 2007 U.S. dollars). Linear regressions were conducted to assess how costs incurred by patients with resistant infections versus those incurred by uninfected or susceptible-organism-infected controls varied according to (1) costs incurred by control subjects; (2) study population characteristics; (3) methodological factors (eg, matching); and (4) length of stay. Results: Estimates of difference in costs incurred by patients with resistant infections versus patients without resistant infections varied between $-27,609 (control costs exceeded case costs) and $126,856. Differences were greater when the costs incurred by control subjects were higher (ie, when the underlying cost of care was high). Study-adjusted cost differences were greater for bloodstream infections (vs. any other infection site), for studies that reported median (vs. mean) costs, for studies that reported total (vs. postinfection or infection-associated) costs, for studies that used uninfected (vs. susceptible-organism-infected) controls, and for studies that did not match or adjust for length of stay before infection. Conclusion: The cost of antimicrobial resistance seems to vary with the underlying cost of care. Increased costs of resistance are partially explained by longer length of stay for patients with resistant infections. Further research is needed to assess whether interventions should be differentially targeted at the highest cost cases.

AB - Background: Existing estimates of the costs of antimicrobial resistance exhibit broad variability, and the contributing factors are not well understood. This study examines factors that contribute to variation in these estimates. Methods: Studies of the costs of resistant infections (1995-2009) were identified, abstracted, and stated in comparable terms (eg, converted to 2007 U.S. dollars). Linear regressions were conducted to assess how costs incurred by patients with resistant infections versus those incurred by uninfected or susceptible-organism-infected controls varied according to (1) costs incurred by control subjects; (2) study population characteristics; (3) methodological factors (eg, matching); and (4) length of stay. Results: Estimates of difference in costs incurred by patients with resistant infections versus patients without resistant infections varied between $-27,609 (control costs exceeded case costs) and $126,856. Differences were greater when the costs incurred by control subjects were higher (ie, when the underlying cost of care was high). Study-adjusted cost differences were greater for bloodstream infections (vs. any other infection site), for studies that reported median (vs. mean) costs, for studies that reported total (vs. postinfection or infection-associated) costs, for studies that used uninfected (vs. susceptible-organism-infected) controls, and for studies that did not match or adjust for length of stay before infection. Conclusion: The cost of antimicrobial resistance seems to vary with the underlying cost of care. Increased costs of resistance are partially explained by longer length of stay for patients with resistant infections. Further research is needed to assess whether interventions should be differentially targeted at the highest cost cases.

KW - antibiotic resistance

KW - hospital costs

KW - length of stay

UR - http://www.scopus.com/inward/record.url?scp=77955982258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955982258&partnerID=8YFLogxK

U2 - 10.1097/MLR.0b013e3181e358b9

DO - 10.1097/MLR.0b013e3181e358b9

M3 - Article

VL - 48

SP - 767

EP - 775

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 9

ER -